[Antigenicity of nine synthetic peptides of human immunodeficiency virus]

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

[Antigenicity of nine synthetic peptides of human immunodeficiency virus]

Chung Hua Nei Ko Tsa Chih. 1997;36(2):105-7. Unique Identifier : AIDSLINE MED/99029113
Mao P; He H; Hong S; Department of Virology, 302 Hospital of PLA, Beijing.

Abstract: To establish a ELISA method to detect the infection of human immunodeficiency virus (HIV), we synthesized nine peptides ranging in length between 10-27 amino acid (aa) of HIV located in the regions of gp41, p24 of HIV-1 and gp36 of HIV-2, according to the published amino acid sequence and the position of antigenic determinants of viruses, by a solid-phase method. We detected 10 positive sera of HIV-1 and 4 positive sera of HIV-2 by a indirect ELISA using these synthetic peptides as the coating antigen. The results indicated that all of 10 serum specimens of HIV-1 were positive using SP1, 5, 6, and 7 derived from gp41, and SP7 was the best in antigenicity. The 4 serum specimens of HIV-2 were positive using SP8 and SP9 in the region of gp36 and their antigenicity to HIV-2 were similar, but the antigenicity of SP8 to HIV-1 was higher than that of SP9. All sera of HIV-1 and HIV-2 were positive using SP7 and SP8 as the mixed coating antigen. A comparison of our reagent with UBI reagent in detection of 60 positive and 96 negative control sera for HIV showed that the coincident rate for positive ness was 98.33% (59/60), for negative ness was 100%, and the general coincident rate was 99.36% (155/156). It is concluded that SP7 and SP8 as the mixed coating antigen are applicable in the diagnosis of HIV infection.

Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/DIAGNOSIS Antibodies, Viral/*IMMUNOLOGY Antibody Affinity English Abstract Enzyme-Linked Immunosorbent Assay *Epitopes Human HIV-1/*IMMUNOLOGY HIV-2/*IMMUNOLOGY Immune Sera/*ANALYSIS Peptides/CHEMICAL SYNTHESIS/DIAGNOSTIC USE
990730
A9971127

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .